Home > English
TB-1 can inhibit and kill various viruses, bacteria, fungi, Mycobacterium tuberculosis and other pathogenic microorganisms, while increasing the body's immunity. It has been used for influenza, various types of tuberculosis, various viral pneumonia and bacterial pneumonia, and has achieved remarkable therapeutic effects.
TB-1 has a significant therapeutic effect on the symptoms of fever, fatigue, cough, expectoration of sputum, hemoptysis, dyspnea, low-grade fever and night sweats, pleural effusion, ascites, and lymphadenopathy, and can make pulmonary inflammatory lesions absorb quickly. At the same time, it has effects on various viruses, bacteria, fungi, and Mycobacterium tuberculosis and other microorganisms. Regardless of the mutation of these viruses and Mycobacterium tuberculosis, TB-1 will eliminate these pathogenic microorganisms.
Coronary pneumonia and tuberculosis are prevalent, and there is currently no effective treatment for the constantly mutating new coronavirus and mutated Mycobacterium tuberculosis. The organ damage and drug resistance caused by anti-tuberculosis chemotherapy drugs have seriously affected the treatment of tuberculosis. Therefore, the world now not only needs rapid and sensitive diagnostic methods, but also urgently needs specific therapeutic drugs with less toxic and side effects.
The anti-respiratory infection drug has no drug resistance and no organ damage and it has a remarkable therapeutic effect against respiratory infectious diseases. So it is imminent to promote TB-1 globally.
Observation on the use of anti-respiratory infectious agents in the treatment of tuberculosis
A lot of patients who have been treated in our outpatient clinics have been hospitalized in tuberculosis hospitals before and have been treated with anti-tuberculosis chemotherapy drugs. After the anti-tuberculosis chemotherapy drugs, some patients developed liver and kidney damage to varying degrees [Case 1]; some patients are resistant to anti-tuberculosis chemotherapy drugs [case 2-4]; some patients suffer from pancytopenia and aplastic anemia [case 5]; some patients are allergic to anti-tuberculosis chemotherapy drugs [case 4]; some patients with tuberculous pleurisy, and the pleural effusion did not disappear after repeated hospitalization with anti-tuberculosis chemotherapy drugs and hormones [Case 6]. there were also patients with lymph node stenosis. After several hospitalizations with anti-tuberculosis treatment and several operations, the cervical lymph nodes continued to grow from different parts of the neck [Case 7]; some patients suffered from diabetic tuberculosis [case 8-10], and the blood sugar increased even more after the application of anti-tuberculosis chemotherapy. It is difficult to control, and patients feel that the symptoms of tuberculosis are more serious, so that patients with diabetes and tuberculosis cannot use anti-tuberculosis chemotherapy drugs; there are also lupus erythematosus tuberculosis patients [case 3], due to the side effects of chemotherapy drugs, the damage to lupus erythematosus patients is more serious.
These are all patients with unsatisfactory anti-tuberculosis chemotherapy drugs.
TB-1 has always been used independently in the treatment of tuberculosis without any other anti-tuberculosis drugs. The treatment and observation of these tuberculosis patients and the therapeutic effect of TB-1 are summarized below.
1. Therapeutic effect of drug-resistant tuberculosis:
Some of these patients are drug-resistant after treatment with anti-TB chemotherapy drugs, and some are contracted by drug-resistant TB patients. After treatment with anti-tuberculosis chemotherapeutic drugs, iatrogenic dysbacteriosis causes fungal infections, curly mold, and raptorella spp., these patients are not the objects of our observation and administration. And other drug-resistant tuberculosis patients are all worth of our observation. These patients have stopped anti-tuberculosis chemotherapy drugs due to various reasons before taking TB-1, and the patients are eager to get effective anti-tuberculosis drug treatment. After the patient took TB-1, the clinical symptoms of tuberculosis began to gradually relieve. According to the different symptoms of each patient, it can be summarized as cough, expectoration, hemoptysis, night sweats, high fever, or low-grade fever in the afternoon, fatigue, chest pain, loss of appetite, weight loss, facial haggard, etc. After a few months of treatment, most of these symptoms disappeared, while the patients' appetite and weight increased, the face were rosy and shiny, the patients felt that their physical strength and immunity had recovered, and they could do some lighter housework. Drug-resistant tuberculosis patients [cases 2-4] evaluated that anti-tuberculosis treatment with TB-1 was much more effective than anti-tuberculosis chemotherapy drugs, while TB-1 did not cause side damage to the patient's body.
2. The therapeutic effect of pulmonary tuberculosis:
In these patients, some pulmonary tuberculosis lesions are small and unilateral, some lung lesions are large and unilateral or bilateral, some are accompanied by small cavities, some are accompanied by large cavities, and some patients have hemoptysis. Some patients excrete bacteria, some patients have severe symptoms of tuberculosis, etc. [case 11-21].
A patient with cavitary hemoptysis [case 22] with pulmonary tuberculosis, the hemoptysis was very serious, the patient was admitted to a tuberculosis hospital, and after hemostasis being treated with anti-tuberculosis chemotherapy drugs, the patient continued to cough up blood. The doctor in charge preferred to block the blood vessels in the bleeding area with interventional methods to stop the bleeding. But the patient took TB-1 in stead. After taking TB-1, the bleeding decreased a lot. About 5 days or so, the patient's sputum was bloodshot, and after 7 days, the patient's hemoptysis disappeared. Other patients with pulmonary tuberculosis hemoptysis with a small amount of hemoptysis disappeared 3-5 days after taking TB-1, and almost no hemoptysis occurred again, without the assistance of hemostatic drugs and anti-tuberculosis chemotherapy drugs; there is also a young patient with pulmonary tuberculosis [case 16], due to the cavity formed during hospitalization and the harm of the side effects of anti-tuberculosis chemotherapy drugs, the patient stopped chemotherapy drugs on his own, and took the anti-tuberculosis drug TB-1. The patient took TB-1 for 2 months then the cavity was closed. We analyzed that this was because the patient's cavity formation time was shorter, the patient was young, and the anti-tuberculosis effect of TB-1 was strong, which made the patient recover faster.
In short, after taking TB-1, the symptoms of pulmonary tuberculosis patients have improved significantly. After several months of treatment, the symptoms of tuberculosis of the patients have almost disappeared, and the patients’ lung CTs have been significantly improved. The symptoms of the patients are relieved and gradually disappear, and the lung lesions can be controlled from spreading, and some satellite lesions can be absorbed, so that the patients can quickly return to normal work and study. Therefore, the anti-tuberculosis treatment effect of TB-1 is highly evaluated.
3. Therapeutic effect of tuberculous pleurisy:
Depending on the condition of the patients with tuberculous pleurisy, the duration of taking TB-1 varies. The amount of pleural effusion and the length of time the pleural effusion stays in the body (for example, the pleural effusion in new patients is diluted, severe patients or the patients with pleural effusion without being disappeared for one year is viscous), the age of the patient, the patient's constitution, the severity of the patient's tuberculosis symptoms, the patient's appetite, etc. to determine the time for the patient to take TB-1 drugs.
For most patients with tuberculous pleurisy [case 23-25], the disease course is short and the pleural effusion is in a diluted state. After taking TB-1, the pleural effusion gradually decreases in 5-7 days, and the pleural effusion disappears in 7-14 days. The clinical symptoms of tuberculosis also disappear.
But for those whose tuberculous pleurisy is severe and the disease course is long; for patients with viscous pleural effusion, the pleural effusion needs to be gradually reduced and it will be disappeared 3 months after taking TB-1.
By treating several special patients, we summarize the experience of using TB-1 treatment.
A female patient with tuberculous pleurisy [case 23] presented with low-grade fever, night sweats, and fatigue. Lung CT showed pleural effusion, and T-cell detection for tuberculosis infection results showed that A and B antigens were less than 6, which were negative. According to the patient's clinical symptoms, the patient could be diagnosed as suspected tuberculous pleurisy. After the patient took TB-1 for a week, the symptoms disappeared. The ultrasound results showed that there was no bilateral thoracic cavity, obvious effusion, after taking TB-1 for 2 months, lung CT results showed no symptoms, so we stopped the treatment. 9 months later, blood was collected from the patient for re-examination: TB infection T cell detection, the results showed: A, B antigens is still less than 6 which is negative. We thought that for a new patient with tuberculosis which does not enter the blood of the body immediately, and it takes a certain time. If TB-1 is administered to the patient at earlier, it can prevent tuberculosis from entering the blood of the body and stop the onset of tuberculosis.
There was also a patient with tuberculous pleurisy, who was admitted to a tuberculosis hospital three times within a year [case 6], and was treated with anti-tuberculosis chemotherapy drugs and hormones each time. After the discharge, the patient continued to use anti-tuberculosis chemotherapy drugs and hormone therapy according to the doctor's instructions. After the patient was discharged about 40 days later, he was admitted to the hospital due to a large amount of pleural effusion. Thus the patient was admitted to the tuberculosis hospital three times a year. The 3rd hospitalization was for treatment of right pleural effusion, liver damage and leukopenia. Lung CT: fluid density shadow in the right pleural cavity, local pleural adhesion and thickening; color Doppler ultrasound: the right thoracic cavity can be seen in the posterior axillary line 43×73mm liquid dark area; white blood cells 3.58×109∕L; T-SPOT tuberculosis-infected T cells were detected as positive A＞50, B＞50. Chemotherapy drugs used for anti-tuberculosis treatment are: capreomycin, moxifloxacin, isoniazid sodium p-aminosalicylate, pyrazinamide, ethambutol, clofazimine. The hormone is prednisone acetate. During hospitalization Uric acid increased 601umol∕L; one month after admission, color Doppler result: 28×63mm liquid dark area can be seen in the posterior axillary line of the right thoracic cavity. The doctor in charge explained that because the pleural effusion is thick and difficult to absorb. The patient decided to abandon all anti-tuberculosis chemotherapy drugs and left the hospital. Thus the patient began to take TB-1. Then the liver and kidney function and white blood cell test indicators returned to normal. After taking TB-1 for about half a month, the appetite began to increase. The patient's weight increased by about 5 pounds. The appetite was good, the symptoms of fatigue and fatigue disappeared, and the face was rosy and shiny. 45 days after taking TB-1, the color Doppler ultrasound examination showed that a 28×28mm liquid dark area was seen in the posterior axillary line of the right thoracic cavity, and the amount of liquid was significantly less than the amount of fluid at discharge; white blood cells, red blood cells, hemoglobin, liver function, renal function and urine routine are all within the normal range; the patient has been taking TB-1 for more than 4 months, and the re-examination color Doppler ultrasound showed no abnormality in both chest cavities and pleural effusion disappeared.; T-SPOT tuberculosis-infected T cells detected A>24, B>18, and the T-SPOT index decreased significantly after taking TB-1 compared with the T-SPOT index when using anti-tuberculosis chemotherapy drugs during hospitalization.
In short, for TB-1 treatment, the treatment effect of tuberculous pleurisy is significantly better than that of anti-tuberculosis chemotherapy drugs. After a few years of follow-up, the patient has no recurrence of tuberculous pleurisy, and no tuberculosis lesions appear in other parts of the body.
4. Therapeutic effect of lymph node
Two weeks after the patients with lymph node nuclei took TB-1, the swollen lymph nodes began to shrink gradually.
Mild patients took TB-1 about 2 months later, the enlarged lymph nodes can return to normal or near-normal size.
While severe patients take TB-1 for 5 months, the enlarged lymph nodes can return to normal or near-normal size.
The principle of TB-1 for the treatment of lymph nodes is: if the lymph nodes in the neck or armpit are particularly large and hard (more than 5 cm), they can be surgically removed, except for the lymph nodes that require diagnostic surgery. No surgery is required, including mediastinal lymph nodes. For those patients with common cervical or axillary lymph nodes whose lymph nodes are particularly large and very soft and even palpable, they can be incised and drained. The caseous necrosis inside should be cleaned out, and the dressing at the incision should be changed every day. Since the patient took TB-1 and changed the dressing every day, fresh tissue growth could be seen [case 26], and the incision was flattened in about 14-20 days. However, in patients with lymph node nuclei who use anti-tuberculosis chemotherapy drugs, after incision and drainage, the fresh tissue in the incision grows very slowly or is difficult to grow, and some patients even need to change the drug for a year or form a sinus, which is very painful, of course, these patients may be due to resistance to chemotherapy drugs.
The following is a description of several patients with lymph node nuclei.
1st case, female, 24 years old, suffered from cervical lymph node nuclei for more than half a year. During this period, she stayed in several tuberculosis hospitals. During the treatment with anti-tuberculosis chemotherapy drugs, the cervical lymph nodes were underwent surgery. Later, the lymph nodes recurred and grew repeatedly. A total of four operations were performed on the neck [case 7]. There were incisions everywhere in the neck. After a short time, swollen lymph nodes appeared in the patient's neck, and the patient could see and feel it. When the patient went to the tuberculosis hospital for the fifth operation, he found our outpatient clinic and learned about the anti-tuberculosis effect of TB-1. After the patient took TB-1, the swollen lymph nodes in the neck did not grow again. 7 days after taking TB-1, the patient felt that the swollen lymph nodes in the neck began to shrink. After 2 months of taking TB-1, the patient could not see or feel the swollen lymph nodes. The patient took TB-1 for 4 months. The patient said that it has been more than 3 years since the discontinuation of TB-1. The patient has no swollen lymph nodes in the neck. Now the patient is strong, weighing 125 pounds, and has a very good appetite and rarely catch a cold.
2nd case, male, 19 years old [case 27], suffering from cervical lymph node nuclei, poor appetite, weak body, weighing about 100 pounds, surgically removed the enlarged lymph nodes in the neck, the pathological diagnosis was lymph node nuclei. the patient felt that the anti-tuberculosis chemotherapeutic drugs have many side effects. The patient took TB-1 for 3 months. We followed up the patient nearly 5 years after the patient stopped taking TB-1. The patient said that after taking TB-1, his body became stronger. He rarely caught colds, and his appetite was very good. Now he weighs 140-150 pounds, and the lymph nodes have not recurred.
5. Therapeutic effect of extrapulmonary tuberculosis
The patients with extrapulmonary tuberculosis we treated were: chest wall tuberculosis [case 10], tuberculous meningitis [cases 28, 9], tuberculous peritonitis [cases 10, 29], lymphadenopathy [cases 7, 26-27, 30], These patients were treated earlier and milder. Due to the timely administration of TB-1, the anti-tuberculosis effect was better, such as chest wall tuberculosis, the tuberculous granuloma of the chest wall swollen can disappear quickly; the brain pressure of tuberculous meningitis can be recovered quickly; Bone tuberculosis lesions can be controlled and no longer spread or lesions shrink.
6. The therapeutic effect of diabetic tuberculosis
The patients with diabetic tuberculosis we treat are: diabetic pulmonary tuberculosis [case 8], diabetic tuberculous pleurisy, diabetic cerebral tuberculosis and tuberculous pleurisy coexist [case 9]. These patients have no blood sugar elevation after taking TB-1. The effect of TB-1 is more significant than that of anti-tuberculosis chemotherapy drugs, because anti-tuberculosis chemotherapy drugs can increase blood sugar and affect the treatment of tuberculosis. In addition, the side effects of anti-tuberculosis chemotherapy drugs will cause greater damage to the body of diabetic patients.
7. Therapeutic effect of lupus erythematosus and tuberculosis
A 39-year-old female patient with lupus erythematosus and bilateral pulmonary tuberculosis [case 3] was very severe and resistant to isoniazid and streptomycin. One lung collapsed and cavities formed in the lungs. The patient infected her nephew (17 years old) with tuberculosis, her nephew was also diagnosed with isoniazid and streptomycin-resistant tuberculosis [case 4]. Both of them were admitted to tuberculosis hospital for anti-TB chemotherapy drug treatment. Her nephew, due to anti-tuberculosis chemotherapy drug allergy, the tuberculosis hospital stopped all anti-tuberculosis chemotherapy drugs. After her nephew took TB-1, his tuberculosis clinical symptoms gradually disappeared. He could eat and gain weight, the treatment effect was very significant. The family took the TB-1 taken by the nephew to the female patient with lupus erythematosus and double lung tuberculosis to see if there was hope to save the female patient. After taking TB-1 for one month, the female patient was able to eat and her physical strength improved. With the treatment of TB-1, the female patient can do some light housework, the symptoms of tuberculosis have been greatly improved, and the patient's mental state and face are also much better. She is happy to share her recovery to us since she feels that TB-1 keeps her alive.
We treated more than 200 patients in the trial, and there were more than 80 patients who kept on taking TB-1 and recovered. These recovered patients were followed up regularly, so far no one has relapsed.
More than 140 patients did not adhere to TB-1. We cannot observe these patients due to their own personal habits, such as smoking, sleepless, being picky about food, alcoholic, not following the dietary therapy and precautions we require, interrupting medication, etc., these patients are not the object of our observation.
Through the treatment of tuberculosis patients with TB-1, we found that the therapeutic effect of TB-1 on tuberculosis is very significant. By comparison, the toxic and side effects of anti-tuberculosis chemotherapy drugs are very serious such as organ damage, drug resistance, toxic side effects, etc.
Tuberculosis should be treated in time at the onset, and complete cure should not be delayed. If repeated hospitalizations recur, drug-resistant tuberculosis or multidrug-resistant tuberculosis will eventually develop, or iatrogenic bacteria (fungi, curly mold, Grappus, etc.) infections, which eventually lead to the failure of various organs, are as life-threatening as advanced cancer, and these are difficult to correct. Through our follow-up of tuberculosis patients taking TB-1, after recovery and discontinuation of TB-1, the patient rarely relapses.
The WHO’s plan for 2016-2035 points out that the TB mortality rate in 2020 should be reduced by 35% on the basis of 2015 and 75% in 2025, by 95% in 2035; tuberculosis incidence by 20%, 50% and 90%, respectively. The number of patients with multi-drug resistant TB (MDR-TB) remains high. However, the anti-tuberculosis chemotherapeutic drugs currently used in the world were developed 50 years ago, and the current treatment of mutated Mycobacterium tuberculosis is very unsatisfactory. It is still very difficult to meet the plan to reduce TB mortality by 95% by 2035.
There is no disease as destructive and eye-catching as tuberculosis. For thousands of years, the struggle of human beings against tuberculosis has never stopped. To stop tuberculosis, it is more important to have specific anti-tuberculosis drugs that do not cause damage and drug resistance to the body of tuberculosis patients.
TB-1 is the answer which has many advantages in the treatment of tuberculosis, such as: no organ damage to patients; no drug resistance; no toxic side effects observed; the most important thing is that it can be used independently without the aid of anti-tuberculosis chemotherapy drugs. TB-1 brings the hope of anti-tuberculosis treatment to those tuberculosis patients who cannot use anti-tuberculosis chemotherapy drugs, and can also treat patients suspected of tuberculosis, control the incidence, drug resistance, and mortality of tuberculosis, and at the same time prevent outbreak of drug-resistant tuberculosis. TB-1 allows us to achieve the goal of WHO.
A summary of TB-1 in the treatment of tuberculosis patients:
Cases:
1. Male, 44 years old with tuberculous pleurisy, severe liver function damage after anti-tuberculosis chemotherapy drug treatment, glutamate aminotransferase 2178.00 U/L, pleural effusion did not disappear, the hospital stopped the use of anti-tuberculosis chemotherapy drugs, and carried out liver protection. After the liver function returned to normal, the patient began to look for other anti-tuberculosis drug treatment, and began to take TB-1. After taking TB-1 for 4 months, his pleural effusion was completely absorbed. He recovered and there has been no recurrence so far.
2. Male, 43 years old, was admitted to hospital for pulmonary tuberculosis on March 2, 2017, and was later detected by the tuberculosis hospital to be resistant to rifampicin and streptomycin. After treatment with anti-tuberculosis chemotherapy drugs, the patient developed increased uric acid, aspartate aminotransferase and alanine aminotransferase increased and doubled higher than the normal high value. The patient felt that the symptoms of tuberculosis not only did not disappear, but also tended to aggravate. Fatigue, obvious weight loss, and weight loss from more than 140 pounds to 110 pounds. Symptoms such as anorexia appears. After the patient was discharged from the hospital, he stopped using anti-tuberculosis chemotherapy drugs instead by taking TB-1. After TB-1, TB symptoms disappeared, weight gained and appetite recovered. After 9 months of taking TB-1, the lung CT lesions were stable and did not develop. The patient was tested for drug-resistant bacteria in sputum by local tuberculosis control on 2019-10-1, and the result was negative. At present, the patient feels strong and has not developed tuberculosis so far.
3. Female, 39 years old, with pulmonary tuberculosis cavity, and suffering from lupus erythematosus. One lung collapsed, she was admitted to tuberculosis hospital many times. Repeatedly used anti-tuberculosis chemotherapy drugs, the patient developed resistance to isoniazid and rifampicin. Weight loss, weakness, unable to eat, and finally the patient asked to stop using anti-tuberculosis chemotherapy drugs. After taking TB-1, the symptoms of tuberculosis began to gradually reduce, the patient had an appetite to eat and gained weight. She felt energetic and could do some housework,. She thought that taking TB-1 allows her to survive, and the patient is still feeling well.
4. Male, 17 years old, with pulmonary tuberculosis, resistant to isoniazid and rifampicin, admitted to a tuberculosis hospital. Due to allergy to anti-tuberculosis chemotherapy drugs, the hospital stopped chemotherapy drug treatment. The patient took TB-1 instead. After 4 months of taking TB-1, he was recovered and there has been no recurrence.
5. Male, 44 years old, was admitted to the tuberculosis hospital with tuberculous pleurisy. Due to the patient suffered from aplastic anemia, the tuberculosis hospital stopped anti-tuberculosis chemotherapy drug treatment. The patient chose TB-1. After 4 months of taking TB-1, he was recovered and there has been no recurrence.
6. Female, 27 years old, with chest tightness and shortness of breath, was admitted to a tuberculosis hospital with right-sided tuberculous pleurisy on January 22, 2015, and was treated with anti-tuberculosis chemotherapy drugs. Because the pleural effusion did not disappear, the patient was admitted to tuberculosis hospital three times in one year. Finally the patient stopped anti-tuberculosis chemotherapy due to liver damage. After the patient took TB-1, the pleural effusion is gradually absorbed. After 4 months of taking TB-1, he was recovered and there has been no recurrence.
7. Female, 24 years old, with cervical lymph node nuclei. She was admitted to the tuberculosis hospital many times. Due to the unsatisfactory treatment of anti-tuberculosis chemotherapy drugs, the patient's cervical lymph node nuclei often recur. In order to remove the lymph nodes in the patient's neck, the patient had undergone multiple operations on the neck, and the neck was scarred. The patient requested to stop using anti-tuberculosis chemotherapy drugs. The patient chose TB-1. After 4 months of taking TB-1, he was recovered and there has been no recurrence.
8. Male, 58 years old, with diabetes and tuberculosis. He was admitted to a tuberculosis hospital many times for anti-tuberculosis chemotherapy drug treatment. Due to the unsatisfactory treatment effect, the patient requested to stop using the anti-tuberculosis chemotherapy drug treatment. The patient took TB-1. Nine months later, his condition was stable.
9. Male, 41 years old, with diabetes, pulmonary tuberculosis, secondary infection in the lungs, tuberculous meningitis. He was admitted to a tuberculosis hospital many times and was treated with anti-tuberculosis chemotherapy drugs. Due to the unsatisfactory treatment effect, the patient requested to stop the use of anti-tuberculosis chemotherapy drugs. The patient started taking TB-1. After 4 months of taking TB-1, he was recovered and there has been no recurrence.
10. Male, 57 years old, with diabetes mellitus, bilateral pulmonary tuberculosis, emphysema, bilateral pleural effusion, pleural thickening and adhesion, pulmonary adhesion, abdominal encapsulated effusion, swollen lymph nodes in the upper septum. The patient's right back chest wall tuberculosis is about 10cm x 10cm in size. The patient was admitted to the tuberculosis hospital for many times and was treated with anti-tuberculosis chemotherapy drugs, but the treatment effect was not satisfactory. The patient was too weak to undergo surgical resection at that time. The patient requested to stop using anti-tuberculosis chemotherapy drugs. After the patient took TB-1 for 9 months, the tumor in the right back chest wall was significantly reduced, no longer enlarged, and the condition was stable.
11. Female, 50 years old, with pulmonary tuberculosis, tuberculous fundus choroiditis, tuberculosis infection T cell test +, anti-tuberculosis chemotherapy drug treatment was not satisfactory after admission, the patient requested to stop using anti-tuberculosis chemotherapy drug treatment. After taking TB-1 for 5 months, the condition was stable and there was no recurrence.
12. Female, 51 years old, with pulmonary tuberculosis. She was admitted to a tuberculosis hospital and was treated with anti-tuberculosis chemotherapy drugs. The patient could not endure the side effects of anti-tuberculosis chemotherapy drugs, so she asked stopping chemotherapy drugs. The patient started taking TB-1 for 4 months, the patient recovered and there has been no recurrence so far.
13. Female, 20 years old, with double pulmonary tuberculosis, was admitted to a tuberculosis hospital and was treated with anti-tuberculosis chemotherapy drugs. The patient could not undertake the side effects of anti-tuberculosis chemotherapy drugs and asked to stop using anti-tuberculosis chemotherapy drugs. After taking TB-1 for 3 months, the patient recovered and there has been no recurrence so far.
14. Male, 37 years old, with pulmonary tuberculosis, was admitted to a tuberculosis hospital and was treated with anti-tuberculosis chemotherapy drugs. Since the patient could not endure the side effects of anti-tuberculosis chemotherapy drugs, he requested to stop chemotherapy drug treatment. The patient started taking TB-1. 3 months later, the patient recovered and there has been no recurrence so far.
15. Female, 29 years old, with secondary pulmonary tuberculosis, left lung cavity formation, sputum culture +, lung infection, hemoptysis, T-cell test for tuberculosis infection +, admitted to tuberculosis hospital and treated with anti-tuberculosis chemotherapy drugs and hemostatic drugs After treatment, the patient still often coughs up blood, and has weight loss, weakness, night sweats, cough and sputum, no appetite and can't eat. Due to the side effects of anti-tuberculosis chemotherapy drugs, she stopped chemotherapy drugs. After the patient started taking TB-1, there was no hemoptysis. The above symptoms gradually disappeared. She had an appetite and could eat, and the left lung cavity was closed. 4 months after taking TB-1, the patient recovered and there has been no recurrence. Two years later, the patient gave birth to a second child. Now both mother and child are healthy.
16. Female, 22 years old, with pulmonary tuberculosis, accompanied by cavitation, T cell test for tuberculosis infection +, admitted to a tuberculosis hospital, treated with anti-tuberculosis chemotherapy drugs. Due to repeated recurrence, mycoplasma infection, increased uric acid, and the treatment effect is not ideal, the patient requested to stop using anti-tuberculosis chemotherapy drugs. The patient took TB-1 for 5 months, and his condition was stable.
17. Male, 27 years old, with pulmonary tuberculosis, hemoptysis, admitted to a tuberculosis hospital for anti-tuberculosis chemotherapy drug treatment. Soon the patient developed liver damage, so the hospital stopped chemotherapy drugs then for liver protection treatment. When the patient's liver function recovered, the patient began to take TB-1, and the patient recovered and there has been no recurrence so far.
18. Female, 21 years old, with secondary pulmonary tuberculosis, intrapulmonary infection, admitted to tuberculosis hospital for anti-tuberculosis chemotherapy drug treatment. Tuberculosis infection T cell detection +, after a period of treatment, the patient felt that the anti-tuberculosis chemotherapy drug treatment effect was not satisfactory and anti-tuberculosis chemotherapy drugs have many side effects. She asked to stop using anti-tuberculosis chemotherapy drugs. The patient began to take TB-1 for about 4 months. After the recovery there has been no recurrence.
19. Female, 25 years old, with pulmonary tuberculosis, hemoptysis, admitted to a tuberculosis hospital for anti-tuberculosis chemotherapy drug treatment. Tuberculosis infection T cell test +. The patient chose TB-1 since he could not afford the hospitalization fee. After taking TB-1 for 4 months his condition was stable, and no symptoms of tuberculosis appeared.
20. Male, 50 years old, with double pulmonary tuberculosis for many years. He has been taking anti-tuberculosis chemotherapy drugs for many years, but the patient felt that the treatment effect was not satisfactory. After 6 months of taking TB-1, his condition was stable.
21. Male, 62 years old, with secondary pulmonary tuberculosis, accompanied by cavitation, hemoptysis, and intrapulmonary infection. The patient had a history of pulmonary tuberculosis and was admitted to a tuberculosis hospital for many times. The treatment effect of tuberculosis chemotherapy drugs was not satisfactory, so the patient requested to stop taking them. After 5 months of taking TB-1, he was recovered.
22. Male, 46 years old, with secondary pulmonary tuberculosis, hemoptysis, was admitted to a tuberculosis hospital and treated with anti-tuberculosis chemotherapy drugs. During the treatment, the patient's hemoptysis was not controlled, and the patient requested to stop using anti-tuberculosis chemotherapy drugs. The patient chose TB-1. The hemoptysis gradually decreased after the patient took TB-1. The patient stopped hemoptysis soon. The patient took TB-1 for 4 months, the condition was stable, there was no further hemoptysis and TB symptoms.
23. Female, 19 years old, with suspected tuberculous pleurisy and pleural effusion. The patient took TB-1 for a week and the pleural effusion disappeared. The patient recovered and there has been no recurrence so far.
24. Female, 41 years old, with tuberculous pleurisy and pleural effusion. She was admitted to a tuberculosis hospital and treated with anti-tuberculosis chemotherapy drugs. After a period of chemotherapy drug treatment, the patient's pleural effusion did not disappear. She asked to stop using anti-tuberculosis chemotherapy drugs. After taking TB-1, the pleural effusion disappeared quickly. She recovered after taking TB-1 for 4 months, and there has been no recurrence so far.
25. Male, 71 years old, with secondary pulmonary tuberculosis, bilateral pleural and pericardial effusion, admitted to a tuberculosis hospital for anti-tuberculosis treatment. The patient's pleural effusion did not disappear after anti-tuberculosis chemotherapy drug treatment. Since old age patient is not suitable for anti-tuberculosis chemotherapy drugs, the patient asked to stop using anti-tuberculosis chemotherapy drugs. The patient chose TB-1 treatment. After the patient took TB-1 for half a month, the bilateral pleural and pericardial effusions disappeared, and tuberculosis symptoms disappeared. The patient recovered after taking TB-1 for 4 months, and there has been no recurrence so far.
26. Female, 26 years old, with pulmonary tuberculosis and axillary lymph node nuclei. She was admitted to a tuberculosis hospital for many times. She underwent axillary lymphadenectomy and was treated with anti-tuberculosis chemotherapy drugs. The patient requested to stop the anti-tuberculosis chemotherapy drug treatment and toke TB-1, the patient recovered after taking TB-1 for 4 months, and there has been no recurrence.
27. Male, 21 years old, with lymph nodes in the neck, was admitted to a tuberculosis hospital for anti-tuberculosis chemotherapy drugs, and the cervical lymph nodes were surgically removed. The patient found that the anti-tuberculosis chemotherapy drugs had many side effects, and asked to stop the anti-tuberculosis chemotherapy drugs. The patient selected anti-tuberculosis drug TB-1. He recovered and there has been no recurrence so far.
28. Male, 22 years old, with tuberculous meningitis and lung infection, was admitted to a tuberculosis hospital for anti-tuberculosis chemotherapy drugs. The patient suffered from mucopolysaccharidosis, so anti-tuberculosis chemotherapy drugs could not be used. He chose anti-tuberculosis drugs TB-1. He recovered after taking TB-1 3 months, and there has been no recurrence so far.
29. Female, 23 years old, with secondary pulmonary tuberculosis, tuberculous pleurisy and peritonitis, was admitted to a tuberculosis hospital for anti-tuberculosis chemotherapy drug treatment. After anti-tuberculosis chemotherapy drug treatment, pleural effusion and ascites did not disappear, the patient felt that anti-tuberculosis chemotherapy was unsatisfactory. She requested to stop anti-tuberculosis chemotherapy drug treatment, and chose anti-tuberculosis drug TB-1 treatment. After the patient took TB-1 for 1 month, pleural effusion and ascites were gradually absorbed almost completely. The effect of anti-tuberculosis treatment is obvious. The patient recovered after taking TB-1 for 4 months, and there has been no recurrence so far.
30. Female, 54 years old, with lymph node stenosis in the right neck. She was admitted to a tuberculosis hospital for anti-tuberculosis chemotherapy drug treatment. Due to the many side effects of anti-tuberculosis chemotherapy drugs, the patient requested to stop anti-tuberculosis chemotherapy drug treatment. She chose anti-tuberculosis drugs TB-1 treatment. After TB-1 treatment, the cervical lymph node nuclei gradually shrunk. TB-1 anti-tuberculosis treatment effect is remarkable, the patient recovered after taking TB-1 for 4 months, and there is no recurrence so far.
Contact
Email:info(at)equl.com